Call to Order and Opening Remarks Peter Gross, M.D.
Introduction of Committee
of Interest Statement
Issue: Current screening methods to assess sound alike and look alike proprietary
drug names, in order to reduce the incidence of medication error resulting
from look alike and sound alike names.
Welcome Paul S. Seligman, M.D., M.P.H.
Director, Office of Pharmaco-
epidemiology & Statistical Science
Office of Drug Safety
Proprietary Name Evaluation at FDA Jerry Phillips, R.Ph.
Medication Error Prevention, ODS, FDA
PhRMA: Views on Trademark Evaluation Robert E. Lee, Jr., J.D.
Assistant General Patent Counsel
Eli Lilly and Company
and Research Manufacturer’s
Advancing the Science of Drug Trade Name Paul Seligman, M.D., M.P.H.
Automatic String Matching for Reduction of Bonnie Dorr, Ph.D.
Drug Name Confusion Assistant Professor
Dept. of Computer Science
Evaluating Drug Name Confusion Using R.F. Shangraw, Jr., Ph.D.
Using Expert Panels CEO
Project Performance Corporation
Focus Group Methodology Miriam Bar-Din Kimel, Ph.D.
Senior Project Manager MEDTAP International
11: 05 Use of Laboratory and Other Simulations in Kraig Schell, Ph.D.
Assessing Drug Name Confusion Assistant Professor
Dept. of Psychology
Quantitative Evaluation of Drug Name Safety Sean Hennessy, PharmD, Ph.D.
Using Mock Pharmacy Practice Assistant Professor
Dept. of Epidemiology & Pharmacology
Center for Clinical Epidemiology &
Open Public Hearing
Introduction of the Issues for Discussion Paul Seligman, M.D., M.P.H.
Committee Discussion of Issues/Questions
Continuation of Committee Discussion